Oculis Holding AG (OCS) Non Operating Income (2022 - 2026)
Oculis Holding AG (OCS) recorded quarterly Non Operating Income of -$1.1 million in Q1 2026, up 70.71% quarter-over-quarter from -$3.8 million in Q4 2025, and down 569.4% on a YoY basis from $239133.9 in Q1 2025.
Oculis Holding AG (OCS) Non Operating Income (2022 - 2026) Analysis & Trends
Oculis Holding AG's Non Operating Income history runs 5 years deep, the most recent figure standing at -$1.1 million for Q1 2026.
- In Q1 2026, Non Operating Income fell 569.4% year-over-year to -$1.1 million; the TTM figure through Mar 2026 stood at $6.9 billion (up 389.78% YoY), while the FY2025 annual figure was -$21.9 million, down 50.39% from the prior year.
- Non Operating Income was -$1.1 million for Q1 2026 at Oculis Holding AG, up from -$3.8 million in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of $6.9 billion in Q3 2025 to a low of -$2.4 billion in Q3 2024.
- Historically, Non Operating Income has averaged $279.9 million across 5 years, with a median of -$1.7 million in 2023.
- The sharpest annual moves came in 2024 and 2025: Non Operating Income tumbled 45430.84% in 2024, then jumped 391.6% in 2025.
- A 5-year view of Non Operating Income shows it stood at $2.0 million in 2022, then plunged by 118.59% to -$369772.3 in 2023, then plunged by 3491.22% to -$13.3 million in 2024, then jumped by 71.14% to -$3.8 million in 2025, then soared by 70.71% to -$1.1 million in 2026.
- The last three Non Operating Income figures came in at -$1.1 million (Q1 2026), -$3.8 million (Q4 2025), and $6.9 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | 5.75 Mn |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | 444,000.00 |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | - |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | 9.35 Mn |
| 10 | Oculis Holding AG | 8.23 Bn | 7.92 Bn | - | -1.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.12 Mn |
| Dec 31, 2025 | -3.83 Mn |
| Sep 30, 2025 | 6.87 Bn |
| Jun 30, 2025 | -5.59 Mn |
| Mar 31, 2025 | 239,133.87 |
| Dec 31, 2024 | -13.28 Mn |
| Sep 30, 2024 | -2.36 Bn |
| Jun 30, 2024 | 1.85 Mn |
| Mar 31, 2024 | -842,076.50 |
| Dec 31, 2023 | -369,772.27 |
| Sep 30, 2023 | -5.17 Mn |
| Jun 30, 2023 | -2.24 Mn |
| Mar 31, 2023 | -1.15 Mn |
| Dec 31, 2022 | 1.99 Mn |
| Sep 30, 2022 | -3.18 Mn |
| Jun 30, 2022 | -3.18 Mn |